Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

##STR00001##

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula ##STR00001##
wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are each a hydrogen atom or a substituent; Q.sup.1 and Q.sup.2, and Q.sup.3 and Q.sup.4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y.sup.1, Y.sup.2 and Y.sup.3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y.sup.1, and Y.sup.1 and Y.sup.2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z.sup.1, Z.sup.2 and Z.sup.3 are each H or a substituent, or a salt thereof.

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula ##STR00001##
wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are each a hydrogen atom or a substituent; Q.sup.1 and Q.sup.2, and Q.sup.3 and Q.sup.4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y.sup.1, Y.sup.2 and Y.sup.3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y.sup.1, and Y.sup.1 and Y.sup.2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z.sup.1, Z.sup.2 and Z.sup.3 are each H or a substituent, or a salt thereof.

The present invention is related to an improved process for the preparation of amino-substituted 4,5,6,7-tetrahydrobenzothiazole compounds of formula I, such as the compound 2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention further relates to an improved synthesis of (R)-2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention also relates to the methods and intermediates associated with the synthetic process.

The present invention is related to an improved process for the preparation of amino-substituted 4,5,6,7-tetrahydrobenzothiazole compounds of formula I, such as the compound 2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention further relates to an improved synthesis of (R)-2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention also relates to the methods and intermediates associated with the synthetic process.

Compounds of the formula I ##STR00001##
in which R.sup.1, R.sup.4, R.sup.6, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in claim 1,
are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Compounds of the formula I ##STR00001##
in which R.sup.1, R.sup.4, R.sup.6, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in claim 1,
are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.